IL237742A0 - Laquinimod and pridofidine for the treatment of neurodegenerative diseases - Google Patents
Laquinimod and pridofidine for the treatment of neurodegenerative diseasesInfo
- Publication number
- IL237742A0 IL237742A0 IL237742A IL23774215A IL237742A0 IL 237742 A0 IL237742 A0 IL 237742A0 IL 237742 A IL237742 A IL 237742A IL 23774215 A IL23774215 A IL 23774215A IL 237742 A0 IL237742 A0 IL 237742A0
- Authority
- IL
- Israel
- Prior art keywords
- pridopidine
- laquinimod
- neurodegenerative disorders
- treating neurodegenerative
- treating
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title 1
- 229950003764 pridopidine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Mechanical Engineering (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261706695P | 2012-09-27 | 2012-09-27 | |
| US201361879004P | 2013-09-17 | 2013-09-17 | |
| PCT/US2013/062482 WO2014052933A1 (en) | 2012-09-27 | 2013-09-27 | Laquinimod and pridopidine for treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL237742A0 true IL237742A0 (en) | 2015-05-31 |
Family
ID=50339469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL237742A IL237742A0 (en) | 2012-09-27 | 2015-03-15 | Laquinimod and pridofidine for the treatment of neurodegenerative diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (7) | US20150209346A1 (OSRAM) |
| EP (1) | EP2900330A4 (OSRAM) |
| CN (1) | CN104902958A (OSRAM) |
| AU (1) | AU2013323131A1 (OSRAM) |
| BR (1) | BR112015006623A2 (OSRAM) |
| CA (1) | CA2884781A1 (OSRAM) |
| EA (1) | EA201590655A8 (OSRAM) |
| HK (2) | HK1214553A1 (OSRAM) |
| IL (1) | IL237742A0 (OSRAM) |
| IN (1) | IN2015DN03219A (OSRAM) |
| MX (1) | MX2015003608A (OSRAM) |
| WO (1) | WO2014052933A1 (OSRAM) |
| ZA (1) | ZA201502600B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| DK2146961T3 (da) * | 2007-04-12 | 2014-04-28 | Ivax Int Gmbh | N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler |
| AU2011298382A1 (en) | 2010-09-03 | 2013-05-02 | Teva Pharmaceuticals International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| KR20140075703A (ko) | 2011-09-07 | 2014-06-19 | 아이백스 인터내셔널 게엠베하 | 프리도피딘 하이드로클로라이드의 다형 형태 |
| US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| KR102316933B1 (ko) | 2013-06-21 | 2021-10-26 | 프리레니아 뉴로테라퓨틱스 엘티디. | 헌팅턴병 치료를 위한 프리도피딘의 용도 |
| BR112016014507A2 (pt) * | 2013-12-20 | 2018-05-22 | Teva Pharma | uso de laquinimod para retardar progressão da doença de huntington |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| CA2961187A1 (en) * | 2014-09-16 | 2016-03-24 | Teva Pharmaceuticals Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
| JP2018505147A (ja) | 2014-12-22 | 2018-02-22 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | プリドピジンのｌ−酒石酸塩 |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017015615A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
| BR112020003119A2 (pt) * | 2017-08-14 | 2020-10-13 | Prilenia Neurotherapeutics Ltd. | método de tratamento de esclerose lateral amiotrófica com pridopidina |
| IL319305A (en) * | 2019-03-15 | 2025-04-01 | Prilenia Neurotherapeutics Ltd | Pridopidine and analogues for the treatment of mitochondrial diseases and disorders and symptoms associated with these diseases |
| EA202193190A1 (ru) * | 2019-06-12 | 2022-03-24 | Прилиния Ньюротерапьютикс Лтд. | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008155357A2 (en) * | 2007-06-18 | 2008-12-24 | A. Carlsson Research Ab | Use of dopamine stabilizers |
| WO2010057006A1 (en) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
| ES2731052T3 (es) * | 2009-08-10 | 2019-11-13 | Active Biotech Ab | Tratamiento de la enfermedad de Huntington usando laquinimod |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| JP2013544887A (ja) * | 2010-12-07 | 2013-12-19 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症患者において疲労を軽減し、機能状態を改善し、生活の質を改善するための、ラキニモド（ｌａｑｕｉｎｉｍｏｄ）の使用 |
-
2013
- 2013-09-27 IN IN3219DEN2015 patent/IN2015DN03219A/en unknown
- 2013-09-27 CN CN201380050913.8A patent/CN104902958A/zh active Pending
- 2013-09-27 MX MX2015003608A patent/MX2015003608A/es unknown
- 2013-09-27 AU AU2013323131A patent/AU2013323131A1/en not_active Abandoned
- 2013-09-27 EA EA201590655A patent/EA201590655A8/ru unknown
- 2013-09-27 HK HK16102362.8A patent/HK1214553A1/zh unknown
- 2013-09-27 HK HK15112317.4A patent/HK1211525A1/xx unknown
- 2013-09-27 EP EP13840841.4A patent/EP2900330A4/en not_active Withdrawn
- 2013-09-27 US US14/426,327 patent/US20150209346A1/en not_active Abandoned
- 2013-09-27 BR BR112015006623A patent/BR112015006623A2/pt active Search and Examination
- 2013-09-27 US US14/040,586 patent/US20140088140A1/en not_active Abandoned
- 2013-09-27 CA CA2884781A patent/CA2884781A1/en active Pending
- 2013-09-27 WO PCT/US2013/062482 patent/WO2014052933A1/en not_active Ceased
-
2015
- 2015-03-15 IL IL237742A patent/IL237742A0/en unknown
- 2015-04-17 ZA ZA2015/02600A patent/ZA201502600B/en unknown
-
2017
- 2017-07-20 US US15/655,580 patent/US20170319569A1/en not_active Abandoned
- 2017-11-02 US US15/801,703 patent/US20180133209A1/en not_active Abandoned
-
2018
- 2018-05-08 US US15/974,112 patent/US20180250285A1/en not_active Abandoned
- 2018-08-30 US US16/117,604 patent/US20180369228A1/en not_active Abandoned
- 2018-12-18 US US16/223,993 patent/US20190117639A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2900330A4 (en) | 2016-05-25 |
| CA2884781A1 (en) | 2014-04-03 |
| US20140088140A1 (en) | 2014-03-27 |
| CN104902958A (zh) | 2015-09-09 |
| US20180250285A1 (en) | 2018-09-06 |
| EP2900330A1 (en) | 2015-08-05 |
| HK1211525A1 (en) | 2016-05-27 |
| AU2013323131A1 (en) | 2015-05-07 |
| MX2015003608A (es) | 2015-06-05 |
| BR112015006623A2 (pt) | 2017-07-04 |
| EA201590655A1 (ru) | 2015-12-30 |
| US20190117639A1 (en) | 2019-04-25 |
| US20180133209A1 (en) | 2018-05-17 |
| IN2015DN03219A (OSRAM) | 2015-10-02 |
| HK1214553A1 (zh) | 2016-07-29 |
| ZA201502600B (en) | 2016-06-29 |
| US20150209346A1 (en) | 2015-07-30 |
| WO2014052933A1 (en) | 2014-04-03 |
| US20180369228A1 (en) | 2018-12-27 |
| US20170319569A1 (en) | 2017-11-09 |
| EA201590655A8 (ru) | 2016-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237742A0 (en) | Laquinimod and pridofidine for the treatment of neurodegenerative diseases | |
| IL267066B (en) | Activin-actrii antagonists and their use for the treatment of bone and other disorders | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| HRP20181976T1 (hr) | Postupci za liječenje poremećaja gubitka kose | |
| IL238416A0 (en) | Preparations and methods for the treatment of diseases caused by protein pathology | |
| ZA201404676B (en) | Compositions and methods for treating metabolic disorders | |
| EP2852349A4 (en) | PROCESS PLANNING SYSTEM | |
| DK3292875T3 (en) | Compositions and methods for treating diseases | |
| IL233140A0 (en) | Device and methods for treating nervous disorders | |
| EP2872146A4 (en) | TETRACYCLIN COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| GB201219873D0 (en) | Diverticulitis treatment | |
| TWI559917B (en) | Methods and compositions for treating neurodegenerative diseases | |
| IL238223A0 (en) | Methods and materials for the treatment of multiple sclerosis and diseases related to it | |
| IL233141B (en) | A pharmaceutical preparation for the treatment of hearing and balance disorders | |
| EP2847158A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISORDERS | |
| PT2861242T (pt) | Disfunções relacionadas com o glúten | |
| IL246286B (en) | A medical preparation for the prevention and treatment of advanced myopia. | |
| ZA201504065B (en) | Therapeutic agent for keratoconjunctive disorders | |
| EP2919856A4 (en) | METHOD AND COMPOSITION FOR THE TREATMENT OF GASTRO-SOPHAGEAL DISORDERS | |
| IL238363A0 (en) | Methods for treating eye diseases | |
| AU2012904982A0 (en) | Device for treating respiratory disorders |